Kiniksa Pharmaceuticals International, plc

Good day and thank you for standing by. Welcome to the Connexa Pharmaceuticals first quarter 2025 earnings conference call. At this time, all participants are on a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, During the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jonathan Kirschenbaum, Investor Relations. Please go ahead.

Thank you, Operator. Good morning, everyone, and thank you for joining Connexa's call to discuss our first quarter 2025 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section. As for the agenda for today's call, our Chief Executive Officer, Sanj K. Patel, will begin with an introduction. Ross Mote, our Chief Commercial Officer, will provide an update on ARCWIS commercial execution. Then Mark Ragosa, our Chief Financial Officer, will review our first quarter 2025 financial results. Finally, Sanj will share closing remarks and kick off the Q&A session, for which Dr. John Paolini, our Chief Medical Officer, and Evan Tesari, our Chief Operating Officer, will also be on the line. Before getting started, Please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I will turn the call over to Sanj.

Thanks, Jonathan, and good morning, everyone. Connexa is off to a great start in 2025, and we're well positioned to build on our strong performance throughout the rest of the year. We've continued to make excellent progress with Arclist and our commercial franchise in recurrent pericarditis, reaching an increasing number of patients and growing to a net product revenue of $137.8 million in the first quarter. Ross will go into additional detail about our first quarter performance in a moment. Before he does, of note, the end of Q1 marks the fourth anniversary of the FDA approval of Arclist in recurrent pericarditis. And the underlying fundamentals that have propelled our commercial success up to this point remain strong. Since launch, we have continued to observe expanding adoption among new and repeat prescribers. greater appreciation for the multi-year duration of disease, and high payer approval rates. Through consistent and effective execution, we've delivered this transformative therapy, which is the only FDA-approved treatment for recurrent pericarditis, to thousands of patients, establishing and extending our position as the market leader, driving sustained revenue growth year over year. As a result of our strong Q1 performance, we are increasing the Arclist net sales guidance to between $590 and $605 million from our previous range of between $560 and $580 million. In addition to Arclist, we've been hard at work at advancing KPL 387 in recurrent pericarditis since announcing the program just a couple of months ago. were on track to initiate the phase two slash phase three clinical trial in the middle of this year, with data from the phase two portion expected in the second half of next year, 2026. Additionally, we've maintained a robust financial position and expect to remain cash flow positive on an annual basis, providing the flexibility to continue investing in additional value-creating opportunities cost the business. With that, I'll now turn it over to Ross.